A Phase I/II, 2-Arm, Open Label, Single Centre Study to Investigate the Safety and Effect of Oral GABA Therapy on Beta-Cell Regeneration in Type 1-diabetes Patients
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Gamma amino butyric acid Diamyd (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms ReGenerate-1
- 16 Oct 2018 According to a Diamyd Medical AB media release, recruitment of patients is ongoing to the first part of this trial.
- 10 Sep 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated